Chimeric antigen receptor T Cells Guided by the single-chain Fv of a broadly neutralizing antibody specifically and effectively eradicate virus reactivated from latency in CD4 + T lymphocytes isolated from HIV-1-infected individuals receiving suppressive combined antiretroviral therapy

Journal of Virology

Volumn 90, Issue 21, 2016, Pages 9712-9724

  Liu, Bingfeng ^a   Zou, Fan ^a   Lu, Lijuan ^a   Chen, Cancan ^a   He, Dalian ^a   Zhang, Xu ^a   Tang, Xiaoping ^b   Liu, Chao ^a   Li, Linghua ^b   Zhang, Hui ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; ENVELOPE PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; LOPINAVIR; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BLOCKING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMBINED ANTIRETROVIRAL THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; INFECTION SENSITIVITY; PRIORITY JOURNAL; REBOUND; T LYMPHOCYTE; TREATMENT WITHDRAWAL; VIRUS INFECTIVITY; VIRUS REACTIVATION; CELL LINE; DRUG EFFECT; HEK293 CELL LINE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; VIRUS ACTIVATION; VIRUS LATENCY;

ANTI-HIV AGENTS; ANTIBODIES, BLOCKING; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; HEK293 CELLS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, ANTIGEN, T-CELL; SINGLE-CHAIN ANTIBODIES; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84993996143     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00852-16     Document Type: Article

References (71)

1. Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW, Chomont N. 2010. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science (New York, NY) 329:174-180. http://dx.doi.org/10.1126/science.1191047.
2. Strain MC, Gunthard HF, Havlir DV, Ignacio CC, Smith DM, Leigh-Brown AJ, Macaranas TR, Lam RY, Daly OA, Fischer M, Opravil M, Levine H, Bacheler L, Spina CA, Richman DD, Wong JK. 2003. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A 100:4819-4824. http://dx.doi.org/10.1073/pnas.0736332100.
3. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727-728. http://dx.doi.org/10.1038/nm880.
4. Shan L, Xing S, Yang HC, Zhang H, Margolick JB, Siliciano RF. 2014. Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells. J Antimicrob Chemother 69:28-33. http://dx.doi.org/10.1093/jac/dkt338.
5. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. 2009. The challenge of finding a cure for HIV infection. Science (New York, NY) 323:1304-1307. http://dx.doi.org/10.1126/science.1165706.
6. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. 2010. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10:11-23. http://dx.doi.org/10.1038/nri2674.
7. Liu C, Ma X, Liu B, Chen C, Zhang H. 2015. HIV-1 functional cure: will the dream come true?. BMC Med 13:284. http://dx.doi.org/10.1186/s12916-015-0517-y.
8. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. 2005. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (London, England) 366:549-555. http://dx.doi.org/10.1016/S0140-6736(05)67098-5.
9. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR, Pomerantz RJ. 2001. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98: 3006-3015. http://dx.doi.org/10.1182/blood.V98.10.3006.
10. Goulder PJ, Watkins DI. 2004. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 4:630-640. http://dx.doi.org/10.1038/nri1417.
11. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, Keele BF, Learn GH, Turnbull EL, Salazar MG, Weinhold KJ, Moore S, Letvin N, Haynes BF, Cohen MS, Hraber P, Bhattacharya T, Borrow P, Perelson AS, Hahn BH, Shaw GM, Korber BT, McMichael AJ. 2009. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 206: 1253-1272. http://dx.doi.org/10.1084/jem.20090365.
12. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-485. http://dx.doi.org/10.1038/nature11286.
13. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF. 2012. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36:491-501. http://dx.doi.org/10.1016/j.immuni.2012.01.014.
14. Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H, Margolick JB, Gurer C, Murphy AJ, Valenzuela DM, Yancopoulos GD, Deeks SG, Strowig T, Kumar P, Siliciano JD, Salzberg SL, Flavell RA, Shan L, Siliciano RF. 2015. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517:381-385. http://dx.doi.org/10.1038/nature14053.
15. Dotti G, Gottschalk S, Savoldo B, Brenner MK. 2014. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 257:107-126. http://dx.doi.org/10.1111/imr.12131.
16. Kershaw MH, Westwood JA, Darcy PK. 2013. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 13:525-541. http://dx.doi.org/10.1038/nrc3565.
17. Maus MV, Grupp SA, Porter DL, June CH. 2014. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123: 2625-2635. http://dx.doi.org/10.1182/blood-2013-11-492231.
18. Hinrichs CS, Rosenberg SA. 2014. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 257:56-71. http://dx.doi.org/10.1111/imr.12132.
19. Rosenberg SA, Restifo NP. 2015. Adoptive cell transfer as personalized immunotherapy for human cancer. Science (New York, NY) 348:62-68. http://dx.doi.org/10.1126/science.aaa4967.
20. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. 2013. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509-1518. http://dx.doi.org/10.1056/NEJMoa1215134.
21. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. 2012. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709-2720. http://dx.doi.org/10.1182/blood-2011-10-384388.
22. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. 2015. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (London, England) 385:517-528. http://dx.doi.org/10.1016/S0140-6736(14)61403-3.
23. Porter DL, Levine BL, Kalos M, Bagg A, June CH. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733. http://dx.doi.org/10.1056/NEJMoa1103849.
24. Krebs K, Bottinger N, Huang LR, Chmielewski M, Arzberger S, Gasteiger G, Jager C, Schmitt E, Bohne F, Aichler M, Uckert W, Abken H, Heikenwalder M, Knolle P, Protzer U. 2013. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 145:456-465. http://dx.doi.org/10.1053/j.gastro.2013.04.047.
25. Sautto GA, Wisskirchen K, Clementi N, Castelli M, Diotti RA, Graf J, Clementi M, Burioni R, Protzer U, Mancini N. 2016. Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut 65:512-523. http://dx.doi.org/10.1136/gutjnl-2014-308316.
26. Roberts MR, Qin L, Zhang D, Smith DH, Tran AC, Dull TJ, Groopman JE, Capon DJ, Byrn RA, Finer MH. 1994. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 84:2878-2889.
27. Yang OO, Tran AC, Kalams SA, Johnson RP, Roberts MR, Walker BD. 1997. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci U S A 94:11478-11483. http://dx.doi.org/10.1073/pnas.94.21.11478.
28. Bitton N, Verrier F, Debre P, Gorochov G. 1998. Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120. Eur J Immunol 28:4177-4187. http://dx.doi.org/10.1002/(SICI)1521-4141(199812)28:12<4177 ::AID-IMMU4177>3.0.CO;2-J.
29. Masiero S, Del Vecchio C, Gavioli R, Mattiuzzo G, Cusi MG, Micheli L, Gennari F, Siccardi A, Marasco WA, Palu G, Parolin C. 2005. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther 12:299-310. http://dx.doi.org/10.1038/sj.gt.3302413.
30. Ali A, Kitchen SG, Chen IS, Ng HL, Zack JA, Yang OO. 2016. HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. J Virol 90:6999-7006. http://dx.doi.org/10.1128/JVI.00805-16.
31. Romeo C, Seed B. 1991. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64:1037-1046. http://dx.doi.org/10.1016/0092-8674(91)90327-U.
32. Sahu GK, Sango K, Selliah N, Ma Q, Skowron G, Junghans RP. 2013. Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology 446:268-275. http://dx.doi.org/10.1016/j.virol.2013.08.002.
33. Ni Z, Knorr DA, Bendzick L, Allred J, Kaufman DS. 2014. Expression of chimeric receptor CD4zeta by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells (Dayton, OH) 32:1021-1031. http://dx.doi.org/10.1002/stem.1611.
34. MacLean AG, Walker E, Sahu GK, Skowron G, Marx P, von Laer D, Junghans RP, Braun SE. 2014. A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells. J Med Primatol 43: 341-348. http://dx.doi.org/10.1111/jmp.12137.
35. Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, Rosenberg SA, Dey B, Berger EA. 2015. Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J Virol 89:6685-6694. http://dx.doi.org/10.1128/JVI.00474-15.
36. Zhen A, Kamata M, Rezek V, Rick J, Levin B, Kasparian S, Chen IS, Yang OO, Zack JA, Kitchen SG. 2015. HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. Mol Ther 23:1358-1367. http://dx.doi.org/10.1038/mt.2015.102.
37. McCoy LE, Weiss RA. 2013. Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med 210:209-223. http://dx.doi.org/10.1084/jem.20121827.
38. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio PM, Incesu RB, Eisenreich TR, Bieniasz PD, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC. 2012. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492:118-122. http://dx.doi.org/10.1038/nature11604.
39. Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U, Furze RC, Seaman MS, Prinjha R, Tarakhovsky A, Ravetch JV, Nussenzweig MC. 2014. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158:989-999. http://dx.doi.org/10.1016/j.cell.2014.07.043.
40. Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ, Nason MC, Montefiori D, Moldt B, Poignard P, Diskin R, Bjork-Man PJ, Eckhaus MA, Klein F, Mouquet H, Cetrulo Lorenzi JC, Gazumyan A, Burton DR, Nussenzweig MC, Martin MA, Nishimura Y. 2014. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med 211:2061-2074. http://dx.doi.org/10.1084/jem.20132494.
41. Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Jr, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fatkenheuer G, Schlesinger SJ, Nussenzweig MC. 2015. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522:487-491. http://dx.doi.org/10.1038/nature14411.
42. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (New York, NY) 329:811-817. http://dx.doi.org/10.1126/science.1192819.
43. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (New York, NY) 329:856-861. http://dx.doi.org/10.1126/science.1187659.
44. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. 2010. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843-851. http://dx.doi.org/10.1038/mt.2010.24.
45. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. 2016. CD28 costimulation: from mechanism to therapy. Immunity 44:973-988. http://dx.doi.org/10.1016/j.immuni.2016.04.020.
46. Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, WilsonWH,Rosenberg SA. 2009. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother (Hagerstown, MD) 32:689-702. http://dx.doi.org/10.1097/CJI.0b013e3181ac6138.
47. Zhang Y, Fan M, Geng G, Liu B, Huang Z, Luo H, Zhou J, Guo X, Cai W, Zhang H. 2014. A novel HIV-1-encoded microRNA enhances its viral replication by targeting the TATA box region. Retrovirology 11:23. http://dx.doi.org/10.1186/1742-4690-11-23.
48. Laird GM, Eisele EE, Rabi SA, Lai J, Chioma S, Blankson JN, Siliciano JD, Siliciano RF. 2013. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog 9:e1003398. http://dx.doi.org/10.1371/journal.ppat.1003398.
49. Hernandez JM, Bui MH, Han KR, Mukouyama H, Freitas DG, Nguyen D, Caliliw R, Shintaku PI, Paik SH, Tso CL, Figlin RA, Belldegrun AS. 2003. Novel kidney cancer immunotherapy based on the granulocytemacrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin Cancer Res 9:1906-1916.
50. Schiffner T, Sattentau QJ, Duncan CJ. 2013. Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. Vaccine 31:5789-5797. http://dx.doi.org/10.1016/j.vaccine.2013.10.020.
51. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, Gairin JE, Hahn BH, Oldstone MB, Shaw GM. 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3:205-211. http://dx.doi.org/10.1038/nm0297-205.
52. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, Giangrande P, Luzzi G, Morgan B, Edwards A, McMichael AJ, Rowland-Jones S. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 3:212-217. http://dx.doi.org/10.1038/nm0297-212.
53. Chapuis AG, Casper C, Kuntz S, Zhu J, Tjernlund A, Diem K, Turtle CJ, Cigal ML, Velez R, Riddell S, Corey L, Greenberg PD. 2011. HIV-specific CD8+T cells from HIV+individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. Blood 117:5391-5402. http://dx.doi.org/10.1182/blood-2010-11-320226.
54. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S, Lin AA, Pennathur-Das R, Hege KM. 2000. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 96:785-793.
55. Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, Stevens R, Hazen A, Blaese RM, Chen CC, Leitman SF, Palensky J, Wittes J, Davey RT, Jr, Falloon J, Polis MA, Kovacs JA, Broad DF, Levine BL, Roberts MR, Masur H, Lane HC. 2000. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96:467-474.
56. Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM. 2002. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 5:788-797. http://dx.doi.org/10.1006/mthe.2002.0611.
57. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, Raubitschek A, Forman SJ, Greenberg PD, Riddell SR, Press OW. 2012. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119:3940-3950. http://dx.doi.org/10.1182/blood-2011-10-387969.
58. Gattinoni L, Klebanoff CA, Restifo NP. 2012. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 12:671-684. http://dx.doi.org/10.1038/nrc3322.
59. Dahabieh MS, Battivelli E, Verdin E. 2015. Understanding HIV latency: the road to an HIV cure. Annu Rev Med 66:407-421. http://dx.doi.org/10.1146/annurev-med-092112-152941.
60. Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, Spindler J, Ferris AL, Mellors JW, Kearney MF, Coffin JM, Hughes SH. 2014. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science (New York, NY) 345:179-183.
61. Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, Huang HC, Edlefsen PT, Mullins JI, Frenkel LM. 2014. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science (New York, NY) 345:570-573.
62. Cohn LB, Silva IT, Oliveira TY, Rosales RA, Parrish EH, Learn GH, Hahn BH, Czartoski JL, McElrath MJ, Lehmann C, Klein F, Caskey M, Walker BD, Siliciano JD, Siliciano RF, Jankovic M, Nussenzweig MC. 2015. HIV-1 integration landscape during latent and active infection. Cell 160:420-432. http://dx.doi.org/10.1016/j.cell.2015.01.020.
63. Razooky BS, Pai A, Aull K, Rouzine IM, Weinberger LS. 2015. A hardwired HIV latency program. Cell 160:990-1001. http://dx.doi.org/10.1016/j.cell.2015.02.009.
64. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540-551. http://dx.doi.org/10.1016/j.cell.2013.09.020.
65. Liao HK, Gu Y, Diaz A, Marlett J, Takahashi Y, Li M, Suzuki K, Xu R, Hishida T, Chang CJ, Esteban CR, Young J, Izpisua Belmonte JC. 2015. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun 6:6413. http://dx.doi.org/10.1038/ncomms7413.
66. Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F, Luo B, Alvarez-Carbonell D, Garcia-Mesa Y, Karn J, Mo X, Khalili K. 2014. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad SciUSA111:11461-11466. http://dx.doi.org/10.1073/pnas.1405186111.
67. Anderson J, Banerjea A, Akkina R. 2003. Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides 13:303-312. http://dx.doi.org/10.1089/154545703322616989.
68. Suzuki K, Shijuuku T, Fukamachi T, Zaunders J, Guillemin G, Cooper D, Kelleher A. 2005. Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region. J RNAi Gene Silencing 1:66-78.
69. Yamagishi M, Ishida T, Miyake A, Cooper DA, Kelleher AD, Suzuki K, Watanabe T. 2009. Retroviral delivery of promoter-targeted shRNA induces long-term silencing of HIV-1 transcription. Microbes Infect 11: 500-508. http://dx.doi.org/10.1016/j.micinf.2009.02.003.
70. Mousseau G, Kessing CF, Fromentin R, Trautmann L, Chomont N, Valente ST. 2015. The Tat inhibitor didehydro-cortistatin A prevents HIV-1 reactivation from latency. mBio 6:e00465.
71. Heredia A, Le N, Gartenhaus RB, Sausville E, Medina-Moreno S, Zapata JC, Davis C, Gallo RC, Redfield RR. 2015. Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice. Proc Natl Acad Sci U S A 112:9412-9417. http://dx.doi.org/10.1073/pnas.1511144112.